Title: The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA
Abstract: BJU InternationalVolume 94, Issue 7 p. 963-964 The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA Thomas A. Stamey, Thomas A. Stamey Department of Urology, Stanford University School of Medicine, Stanford, California, USASearch for more papers by this author Thomas A. Stamey, Thomas A. Stamey Department of Urology, Stanford University School of Medicine, Stanford, California, USASearch for more papers by this author First published: 10 November 2004 https://doi.org/10.1111/j.1464-410X.2004.05212.xCitations: 29Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med, 1987; 317: 909–16 2 Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076–83 3 Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. J Am Med Assoc 1999; 281: 1395–400 4 Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum PSA levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology; PSA cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167: 103–11 5 Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The PSA era in the United States is over for prostate cancer: what happened in the past 20 Years? J Urol 2004; in press 6 Stewart CS, Leibovich BC, Weaver AL, Lieber M. M: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86–92 7 Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138–44 8 Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000; 163: 13–20 9 Ries LAG, Eisner MP, Kosary CL et al. National Cancer Institute, Bethesda, MD, 2003. http:seer.cancer.gov.csr19752000 Citing Literature Volume94, Issue7November 2004Pages 963-964 ReferencesRelatedInformation